General Discussion Topics, page-123

The positive we can look forward to in the financials is that Intangible asset impairments should nearly be finished.
Mayne purchased the Teva generics portfolio in August 2016 for US $652M which is approx AU $867M on the 0.752 exchange rate at the time.

CGU (cash generating unit) impairments over the past 4 years are as follows
2018 $184M
2019 $312M
2020 $70M
Dec 20 1/2 yearly $191M
Total impairments of just under $758M

So only $109M of impairments to go before the entire Teva deal is written off and then it's bluesky for Mayne after that!!!

Chartsshout - just because I probably need to spell it out for you. The "blue sky for Mayne" statement is ironic.